Epidermal growth factor receptor expression discrepancies in metastatic colorectal cancer patients treated with cetuximab plus irinotecan-based chemotherapy refractory to irinotecan and oxaliplatin.
作者： Hye-Suk Han , Hee Jin Chang , Yong Sang Hong , Sun Young Kim , Keun Seok Lee
DOI: 10.1007/DCR.0B013E31819EDBF9
关键词:
摘要: PURPOSE:This study was designed to evaluate the efficacy and safety of cetuximab plus irinotecan-based therapy in metastatic colorectal cancer refractory irinotecan oxaliplatin. In addition, discrepancies expression epidermal growth factor receptor were examined by immunohistochemis
sci-hub.se 参考文章(34)
J Tol, M Koopman, NF Antonini, H Sinnige, FAA Valster, JJ Braun, AJ ten Tije, L Mol, JHJM van Krieken, C Punt, Randomized phase III study of capecitabine, oxaliplatin, and bevacizumab with or without cetuximab in advanced colorectal cancer (ACC), the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG) Journal of Clinical Oncology. ,vol. 26, ,(2008) , 10.1200/JCO.2008.26.15_SUPPL.LBA4011
C. Bokemeyer, I. Bondarenko, J. T. Hartmann, F. G. De Braud, C. Volovat, J. Nippgen, C. Stroh, I. Celik, P. Koralewski, KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience Journal of Clinical Oncology. ,vol. 26, pp. 4000- 4000 ,(2008) , 10.1200/JCO.2008.26.15_SUPPL.4000
Per Pfeiffer, Dorte Nielsen, Mette Yilmaz, Anja Iversen, Christian Vejlø, Benny Vittrup Jensen, Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure of irinotecan, oxaliplatin and 5-fluorouracil. Acta Oncologica. ,vol. 46, pp. 697- 701 ,(2007) , 10.1080/02841860601009455
Charles Erlichman, Daniel J. Sargent, New Treatment Options for Colorectal Cancer The New England Journal of Medicine. ,vol. 351, pp. 391- 392 ,(2004) , 10.1056/NEJME048151
Irena Porębska, Antonina Harłozińska, Tomasz Bojarowski, Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumor Biology. ,vol. 21, pp. 105- 115 ,(2000) , 10.1159/000030116
P Pfeiffer, C Qvortrup, J G Eriksen, Current role of antibody therapy in patients with metastatic colorectal cancer. Oncogene. ,vol. 26, pp. 3661- 3678 ,(2007) , 10.1038/SJ.ONC.1210377
B Vincenzi, D Santini, C Rabitti, R Coppola, B Beomonte Zobel, L Trodella, G Tonini, Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial. British Journal of Cancer. ,vol. 94, pp. 792- 797 ,(2006) , 10.1038/SJ.BJC.6603018
Anne F. Buckley, Sanjay Kakar, Comparison of the Dako EGFR pharmDx kit and Zymed EGFR antibody for assessment of EGFR status in colorectal adenocarcinoma. Applied Immunohistochemistry & Molecular Morphology. ,vol. 15, pp. 305- 309 ,(2007) , 10.1097/01.PAI.0000213141.47277.BF
Neal S. Goldstein, Maryiam Armin, Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer. ,vol. 92, pp. 1331- 1346 ,(2001) , 10.1002/1097-0142(20010901)92:5<1331::AID-CNCR1455>3.0.CO;2-M
Akishi Ooi, Takuo Takehana, Xiaoling Li, Shioto Suzuki, Kazuyoshi Kunitomo, Hiroshi Iino, Hideki Fujii, Yasuhisa Takeda, Yoh Dobashi, Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study Modern Pathology. ,vol. 17, pp. 895- 904 ,(2004) , 10.1038/MODPATHOL.3800137